Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Breakthrough Could Lead To New Antimicrobial Drugs
Scientists have discovered exactly how some bacteria act to protect themselves when they are threatened or under attack.

ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect On Pandemic H1N1 Influenza Virus After Oral Administration
ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.
News of the day
Sen. McConnell Says Filibuster Of Supreme Court Nominee Sotomayor Remains Possible
Appearing on CBS" "Face the Nation" on Sunday, Senate Minority Leader Mitch McConnel (R-Ky.) said that Senate Republicans have not ruled out a filibuster on the Supreme Court nomination of Judge Sonia Sotomayor, The Hill reports. Although McConnell acknowledged that he has "consistently opposed filibustering judges," he added that the "precedent was established" when Democrats filibustered Miguel Estrada, an appeals court nominee under former President George W. Bush. When asked to clarify his statement, McConnell added, "The Democrats have firmly established that as a precedent, but that doesn"t mean you are going to use it" (Blake, The Hill, 6/14). McConnell also said that it is "way too early to be talking about whether or not anybody opposes this nominee" (Schieffer, "Face the Nation," CBS, 6/14).According to The Hill, McConnell is the first top GOP senator to state that a filibuster is a possibility, as most other Republicans have said only that it is too early to determine if it should be an option. Republicans "face a difficult path" if they choose to filibuster Sotomayor because party members have long decried judicial filibusters, The Hill reports (The Hill, 6/14).
Medical Devices

New York Times Examines Debate Surrounding Use Of Experimental Treatments In Terminally Ill Patients

Some patient advocates are lobbying to legalize "compassionate use" of experimental drugs for people with terminal illnesses who have exhausted other treatments, prompting a debate about how and when to provide such patients with treatments that could prolong their lives, the New York Times reports. Most insurers do not cover unproven treatments, and physicians have concerns that using experimental treatment could give patients false hope and cause unnecessary pain. Drugmakers are concerned that if there are unfavorable outcomes from providing patients with an unproven treatment, it could hurt the drug"s chances of receiving FDA approval. At the same time, FDA does not want to grant drugs and their makers the opportunity to skip clinical trials. Currently, patients must individually apply to receive treatments through compassionate use (Harmon, New York Times, 5/17). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009